1) Knip M:Environmental triggers and determinants of beta-cell autoimmunity and type 1 diabetes. Rev Endocr Metab Disord 4:213-223, 2003
2) Morimoto J, et al:CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol 173:7017-7024, 2004
3) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
4) Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Effect of intensive therapy on the microvascular complications of type1 diabetes mellitus. JAMA 287:2563-2569, 2002
5) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128:517-523, 1998
6) Keymeulen B, et al:Insulin needs after CD3-antibody therapy in new-onset type1 diabetes. N Engl J Med 352:2598-2608, 2005